News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rhizen Pharmaceuticals S.A. Announces a Scientific Presentation on the Therapeutic Potential of Their Lead Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013


6/12/2013 8:45:46 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the therapeutic potential of its novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6530, in T-cell Lymphomas, at the 18th Congress of the European Hematology Association (EHA) 2013, to be held from June 13-16, at Stockholm, Sweden.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES